• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    1/17/24 4:31:08 PM ET
    $ADAG
    $BFRG
    $BIOR
    $CATX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADAG alert in real time by email

    Gainers

    • Talphera (NASDAQ:TLPH) stock moved upwards by 10.5% to $0.85 during Wednesday's after-market session. The company's market cap stands at $14.4 million.
    • Windtree Therapeutics (NASDAQ:WINT) shares moved upwards by 9.01% to $0.53. The market value of their outstanding shares is at $2.7 million.
    • Passage Bio (NASDAQ:PASG) shares rose 7.02% to $0.98. The market value of their outstanding shares is at $53.9 million.
    • Bullfrog AI Hldgs (NASDAQ:BFRG) stock rose 5.8% to $3.37. The market value of their outstanding shares is at $20.5 million.
    • Biora Therapeutics (NASDAQ:BIOR) stock increased by 5.5% to $1.15. The company's market cap stands at $31.2 million.
    • Coeptis Therapeutics (NASDAQ:COEP) shares rose 5.05% to $0.57. The company's market cap stands at $19.3 million.

    Losers

    • Virpax Pharmaceuticals (NASDAQ:VRPX) shares declined by 13.0% to $0.26 during Wednesday's after-market session. The company's market cap stands at $3.0 million.
    • Adagene (NASDAQ:ADAG) shares declined by 11.26% to $3.55. The company's market cap stands at $155.6 million.
    • Perspective Therapeutics (AMEX:CATX) stock decreased by 10.58% to $0.39. The company's market cap stands at $109.4 million.
    • INVO Bioscience (NASDAQ:INVO) shares decreased by 9.49% to $1.05. The market value of their outstanding shares is at $2.6 million.
    • Compass Therapeutics (NASDAQ:CMPX) shares fell 9.34% to $1.36. The company's market cap stands at $173.3 million.
    • Petros Pharma (NASDAQ:PTPI) shares fell 7.57% to $1.1. The market value of their outstanding shares is at $2.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADAG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAG
    $BFRG
    $BIOR
    $CATX

    CompanyDatePrice TargetRatingAnalyst
    Passage Bio Inc.
    $PASG
    3/31/2026$30.00Outperform
    Oppenheimer
    Perspective Therapeutics Inc.
    $CATX
    2/19/2026$16.00Overweight
    Piper Sandler
    Compass Therapeutics Inc.
    $CMPX
    2/13/2026$15.00Buy
    Craig Hallum
    Passage Bio Inc.
    $PASG
    2/10/2026$21.00Buy
    Chardan Capital Markets
    Compass Therapeutics Inc.
    $CMPX
    1/5/2026Outperform
    William Blair
    Compass Therapeutics Inc.
    $CMPX
    12/3/2025$10.00Mkt Outperform
    Citizens JMP
    Compass Therapeutics Inc.
    $CMPX
    12/3/2025$10.00Buy
    Canaccord Genuity
    Compass Therapeutics Inc.
    $CMPX
    12/3/2025Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ADAG
    $BFRG
    $BIOR
    $CATX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs

    SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (NASDAQ:ADAG), a company committed to transforming the discovery and development of novel antibody-based therapies, today announced the pricing of its underwritten public offering of 18,666,000 American depositary shares, or ADSs, each representing 1.25 ordinary shares of the Company, par value US$0.0001 per share, at the offering price of US$3.75 per ADS, representing the 30-day volume-weighted average price ("VWAP"). The gross proceeds to Adagene from the offering are expected to be approximately US$70.0 million, before deducting underwriting discount and offering expenses. The offe

    4/2/26 7:10:00 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

    Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide clinical supply of muzastotug Collaboration provides additional validation of muzastotug as a potential backbone therapy for next-generation immuno-oncology combinations SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a clinical collaboration with Incyte (NASDAQ:INCY), to evaluate the combination of muzastotug (ADG126) and INCA33890, a TGF

    4/2/26 7:01:00 AM ET
    $ADAG
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response

    Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement over the 13% ORR (5/39) in the combined 10 mg/kg dose cohorts Extended Durability: Median duration of response (mDOR) was not yet reached in the 20 mg/kg cohorts, with responses ongoing beyond 9 months; confirmed mDOR of 6.2 months in the 10 mg/kg cohorts Meaningful Progression-Free Survival (PFS): Median PFS was 6.7 months in the combined 20 mg/kg cohorts, outperforming the 4.8 months observed in the combined 10 mg/kg cohorts Favorable Overall Survival Results: In the 10 mg/kg cohorts (n=41;

    4/2/26 7:00:00 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $BFRG
    $BIOR
    $CATX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Borthwick Kathleen

    4 - Passage BIO, Inc. (0001787297) (Issuer)

    3/18/26 4:07:20 PM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chou William

    4 - Passage BIO, Inc. (0001787297) (Issuer)

    3/18/26 4:06:33 PM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by Adagene Inc.

    3 - Adagene Inc. (0001818838) (Issuer)

    3/18/26 9:05:24 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $BFRG
    $BIOR
    $CATX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Passage BIO with a new price target

    Oppenheimer initiated coverage of Passage BIO with a rating of Outperform and set a new price target of $30.00

    3/31/26 8:17:27 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Perspective Therapeutics with a new price target

    Piper Sandler initiated coverage of Perspective Therapeutics with a rating of Overweight and set a new price target of $16.00

    2/19/26 7:52:02 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Craig Hallum initiated coverage on Compass Therapeutics with a new price target

    Craig Hallum initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $15.00

    2/13/26 8:35:30 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAG
    $BFRG
    $BIOR
    $CATX
    SEC Filings

    View All

    SEC Form 424B5 filed by Adagene Inc.

    424B5 - Adagene Inc. (0001818838) (Filer)

    4/2/26 4:25:35 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Adagene Inc.

    6-K - Adagene Inc. (0001818838) (Filer)

    4/2/26 7:11:55 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Adagene Inc.

    424B5 - Adagene Inc. (0001818838) (Filer)

    4/2/26 7:01:18 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $BFRG
    $BIOR
    $CATX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Hunt Jonathan Robert bought $22,295 worth of shares (11,000 units at $2.03), increasing direct ownership by 23% to 59,800 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    11/17/25 8:01:56 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Director Williamson Robert F Iii bought $19,946 worth of shares (9,498 units at $2.10) (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    11/14/25 8:00:03 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Large owner Lynx1 Capital Management Lp bought $2,261 worth of shares (325 units at $6.96) and bought $221,474 worth of shares (31,683 units at $6.99) (SEC Form 4)

    4 - Passage BIO, Inc. (0001787297) (Issuer)

    9/15/25 8:05:45 PM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAG
    $BFRG
    $BIOR
    $CATX
    Leadership Updates

    Live Leadership Updates

    View All

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Compass Therapeutics Announces Key Leadership Appointments

    BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointments of Arjun Prasad, MBA, MPH as Chief Commercial Officer and Cynthia Sirard, MD as Chief Medical Officer, both effective as of January 1, 2026. "We are thrilled to welcome Arjun and Cyndi to the Compass team. They are highly accomplished leaders with decades of commercial and clinical development experience," said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. "Arjun's world-class expertise in on

    1/5/26 8:00:00 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer

    SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company's Chief Financial Officer, effective today. Mr. Sendek brings extensive experience in senior corporate roles in biotech finance and as a highly respected senior equity research analyst at a number of leading firms. Mr. Sendek previously served as CFO at four biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. He has a successful track record in corporate finance, having completed

    9/4/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $ADAG
    $BFRG
    $BIOR
    $CATX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Windtree Therapeutics Inc.

    SC 13G/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

    11/14/24 7:15:44 PM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Perspective Therapeutics Inc.

    SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

    11/14/24 6:14:40 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Petros Pharmaceuticals Inc.

    SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    11/14/24 5:17:37 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $BFRG
    $BIOR
    $CATX
    Financials

    Live finance-specific insights

    View All

    Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates

    Seismic Pharmaceutical Holdings, LLC acquires the cardiovascular assets and will pay Windtree 20% of any milestone payments, royalty payments or similar economic interests (including all global commercial net revenues) Windtree would receive a payment of $700,000 from Seismic Pharmaceutical Holdings contingent on a financing round resulting in gross cash proceeds of at least $10,000,000 Additionally, Windtree transfers certain cardiovascular development payables to Seismic Pharmaceutical Holdings WARRINGTON, Pa., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (OTCID: WINT), a diversified company with several divisions and focused on becoming

    12/23/25 9:00:00 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

    Updated interim results with an additional ~19 weeks of follow-up since the prior update [212Pb]VMT-α-NET continues to be well-tolerated Objective Response Rate of 44% (7 of 16 patients) in Cohort 2 with SSTR2 expression in all tumors at median follow-up of 41 weeks; 14 of the 16 patients remain free from progression and on studyInitial efficacy data pending for an additional 23 patients in Cohort 2 and 8 patients in Cohort 3, expected during 2026Perspective will hold a conference call on Monday, October 20, 2025 at 8:30 am ET SEATTLE, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering adv

    10/20/25 4:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

    In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe this may suggest that tovecimig could be affecting overall survival in the patient population. As a result, the analysis of the secondary endpoints, including overall survival, is now expected in Q1 2026.In the ongoing Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody) in patients treated in the post-checkpoint inhibitor setting, two deep and confirmed partial responses have been observed to date. A patient with non-small cell lung cancer had a 100% reduction in target le

    8/11/25 7:00:00 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care